Glenmark Pharmaceuticals Limited reported a 30.1% year-on-year increase in Profit After Tax (PAT) to ₹13,620 million for the financial year ended March 31, 2026. Consolidated revenue for FY26 grew 27.5% to ₹169,825 million, driven by robust growth across key geographies and strategic progress in its innovation portfolio. The company's EBITDA for the year stood at ₹45,724 million, reflecting an EBITDA margin of 26.9%. The performance was bolstered by a landmark licensing deal with AbbVie for ISB 2001 and strong momentum in its India and North America businesses.

Q4 FY26 Performance

For the fourth quarter of FY26, consolidated revenue grew to ₹37.6b versus ₹32.6b in the same period last year. EBITDA for the quarter rose sharply to ₹9.4b compared to ₹5.6b year-on-year, with EBITDA margin expanding to 25% from 17.23%. Net profit for the quarter came in at ₹3b versus ₹465m in the corresponding quarter of the previous year. The North America business recorded revenue of ₹9,248 million, a growth of 29.4% YoY, bolstered by deferred out-licensing income recognition for ISB 2001. Net of this income, the core business in the region grew 7.8%. The India business grew 8.2% YoY to ₹10,201 million in Q4, while Europe and Emerging Markets grew 21.4% and 13.7% respectively.

The following table summarises the key Q4 FY26 financial metrics on a year-on-year basis:

Full-Year FY26 Financial Summary

The annual financial performance is captured in the table below:

Operational Highlights

Glenmark's India business delivered strong outperformance, growing at 1.5x the IPM growth. The company ranked as the 2nd fastest-growing company among the top 15 in FY26 as per IQVIA. Key product launches included TEVIMBRA® and BRUKINSA® in Oncology, Nebzmart GFB Smartules® in Respiratory, and GLIPIQ® for Diabetes. RYALTRIS® recorded over 50% growth in secondary sales across commercial markets, with end-to-end commercialization initiated in the USA. The Monroe manufacturing facility received a U.S. FDA EIR with VAI classification, enabling the restart of commercial manufacturing.

Strategic Developments

Ichnos Glenmark Innovation (IGI) secured a landmark licensing deal with AbbVie for ISB 2001, involving an upfront payment of $700 million and a potential total deal value of $1.925 billion. Glenmark will lead commercialization across Emerging Markets. The company also accelerated its Oncology business expansion through in-licensing agreements for Trastuzumab Rezetecan from Hengrui Pharma and Aumolertinib from Hansoh Pharma. Additionally, Glenmark strengthened its generic respiratory portfolio in the US with the first generic approval of Flovent® HFA 44 mcg.

Dividend Recommendation

The Board of Directors recommended a final dividend of 250%, or ₹2.5 per equity share of face value Re. 1 each, for the financial year 2025-26. The payment is subject to the approval of shareholders at the ensuing Annual General Meeting.

Glenmark Pharmaceuticals has outlined a multi-pronged growth strategy for FY27, centred on expanding its respiratory product portfolio while also advancing key assets in dermatology and oncology. The company's plans reflect a broad pipeline of product launches and regulatory milestones targeted for the fiscal year.

Respiratory Portfolio Expansion

Glenmark Pharmaceuticals has identified respiratory products as a key growth driver for FY27. The company aims to strengthen its presence in this therapeutic segment, though specific product details and financial targets were not disclosed in the available information.

Winlevi® Secures EU Approval

A significant regulatory milestone has been achieved with Winlevi® receiving approval from the European Union. The company has planned a commercial launch of the product in FY27, marking its entry into the European market. The following table summarises the key details of this development:

Aumolertinib Launch Anticipated in H2 FY27

In the oncology segment, Glenmark Pharmaceuticals has indicated that the initial launch of Aumolertinib is anticipated in the second half of FY27. This represents a notable pipeline milestone for the company's oncology portfolio. The key details are outlined below:

Strategic Outlook

Glenmark Pharmaceuticals' FY27 agenda encompasses growth across multiple therapeutic areas, with respiratory products, the EU launch of Winlevi®, and the anticipated rollout of Aumolertinib forming the core pillars of its near-term strategy. These developments collectively reflect the company's efforts to advance its product pipeline and broaden its geographic and therapeutic reach during the fiscal year.